NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus

NCCN has added ImmunityBio's ANKTIVA to its Clinical Practice Guidelines for BCG-unresponsive non muscle invasive bladder ...
The American Journal of Managed Care

Papillary Muscle Scarring May Predict Cardiac Death in Dilated Cardiomyopathy

Papillary muscle scarring (papSCAR) is prevalent in one-third of DCM patients and predicts cardiac death independently. The FIDDLE technique significantly improves papSCAR detection sensitivity ...
Nature

Reduction of mitral valve regurgitation caused by acute papillary muscle ischemia

Background A 67-year-old man was admitted to a coronary care unit for non-ST-segment elevation myocardial infarction with complicating acute heart failure. Severe mitral regurgitation was detected by ...
Targeted Oncology

NCCN Adds Nogapendekin to Bladder Cancer Guidelines

The combination of nogapendekin alfa inbakicept-pmln (Anktiva) and Bacillus Calmette-Guérin was added to the NCCN clinical ...
PharmiWeb

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary ...

Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...
Targeted Oncology

NCCN Expands Recommendation for Nadofaragene in BCG-Unresponsive NMIBC

NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...